| Product Unit Size | Cost | Quantity | Stock |
|---|
Dalcetrapib is a cholesterol ester transfer protein (CETP) inhibitor that exhibits anti-atherosclerotic activity. In a clinical setting, dalcetrapib increases HDL levels but has exhibited mixed results regarding cardiovascular disease risk reduction.
| Cas No. | 211513-37-0 |
|---|---|
| Purity | ≥98% |
| Formula | C23H35NO2S |
| Formula Wt. | 389.60 |
| Chemical Name | S-[2-[[1-(2-ethylbutyl)cyclohexanecarbonyl]amino]phenyl] 2-methylpropanethioate |
| IUPAC Name | S-[2-[[1-(2-ethylbutyl)cyclohexanecarbonyl]amino]phenyl] 2-methylpropanethioate |
| Synonym | JTT-705, RO4607381 |
| Solubility | DMSO 78 mg/mL Ethanol 78 mg/mL Water Insoluble |
| Appearance | White Powder |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet |
Schwartz GG, Olsson AG, Abt M, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med. 2012 Nov 29;367(22):2089-99. PMID: 23126252.
Goldberg AS, Hegele RA. Cholesteryl ester transfer protein inhibitors for dyslipidemia: focus on dalcetrapib. Drug Des Devel Ther. 2012;6:251-9. PMID: 23055695.
Robinson JG. Dalcetrapib: a review of Phase II data. Expert Opin Investig Drugs. 2010 Jun;19(6):795-805. PMID: 20465364.